AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director AbbVie issued the following forms today. IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER ...
Monday, December 16, 2019 1 min read
Key Takeaway: NORTH CHICAGO, Ill. , Dec. 16, 2019 /PRNewswire/ -- AbbVie issued the following forms today.
Related Links
21 %
Full Press Release Details
NORTH CHICAGO, Ill. , Dec. 16, 2019 /PRNewswire/ -- AbbVie issued the following forms today.
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
Name of person dealing (Note 1)
Richard Gonzalez
Company dealt in
AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)
Common shares, par value $0.01 per share
Date of dealing
4 December 2019
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
334,589 Common Shares (0.02%)
(2) Derivatives (other than options)
N/A
(3) Options and agreements to purchase/sell
932,154 options (0.06%)
Total
1,266,743 (0.09%)
Class of relevant security:
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit (Note 5)
Gift of common shares
4,000 common shares
$0
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
Date of disclosure
16 December 2019
Contact name
Steven L. Scrogham
Telephone number
847-938-6166
Name of offeree/offeror with which acting in concert
AbbVie Inc.
Specify category and nature of acting in concert status